These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29056527)

  • 1. Flow cytometry: An efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis.
    He L; Su J; Ming M; Bernardo L; Chen T; Gisonni-Lex L; Gajewska B
    J Immunol Methods; 2018 Jan; 452():39-45. PubMed ID: 29056527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation.
    Aboutorabian S; Hakimi J; Boudet F; Montano S; Dookie A; Roque C; Ausar SF; Rahman N; Brookes RH
    Hum Vaccin Immunother; 2015; 11(6):1449-55. PubMed ID: 25997147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation.
    Deshmukh SS; Magcalas FW; Kalbfleisch KN; Carpick BW; Kirkitadze MD
    J Pharm Biomed Anal; 2018 Aug; 157():235-243. PubMed ID: 29866391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro functional assay to measure the biological activity of TB vaccine candidate H4-IC31.
    Ming M; Bernardo L; Williams K; Kolattukudy P; Kapoor N; Chan LG; Pagnon A; Piras F; Su J; Gajewska B; Salha D; Gisonni-Lex L
    Vaccine; 2019 May; 37(22):2960-2966. PubMed ID: 31010716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
    Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
    Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
    van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
    Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
    Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
    EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
    Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
    Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
    Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
    Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells.
    Lenz N; Schindler T; Kagina BM; Zhang JD; Lukindo T; Mpina M; Bang P; Kromann I; Hoff ST; Andersen P; Reither K; Churchyard GJ; Certa U; Daubenberger CA
    Clin Vaccine Immunol; 2015 Jul; 22(7):688-96. PubMed ID: 25924764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
    Jenum S; Tonby K; Rueegg CS; Rühwald M; Kristiansen MP; Bang P; Olsen IC; Sellæg K; Røstad K; Mustafa T; Taskén K; Kvale D; Mortensen R; Dyrhol-Riise AM
    Nat Commun; 2021 Nov; 12(1):6774. PubMed ID: 34811370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions.
    Rhodes SJ; Zelmer A; Knight GM; Prabowo SA; Stockdale L; Evans TG; Lindenstrøm T; White RG; Fletcher H
    Vaccine; 2016 Dec; 34(50):6285-6291. PubMed ID: 27816373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.
    Agger EM; Rosenkrands I; Olsen AW; Hatch G; Williams A; Kritsch C; Lingnau K; von Gabain A; Andersen CS; Korsholm KS; Andersen P
    Vaccine; 2006 Jun; 24(26):5452-60. PubMed ID: 16675077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
    van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
    Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy.
    Alonso-Rodríguez N; Vianello E; van Veen S; Jenum S; Tonby K; van Riessen R; Lai X; Mortensen R; Ottenhoff THM; Dyrhol-Riise AM
    Front Immunol; 2024; 15():1350593. PubMed ID: 38433842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes.
    McMurry J; Sbai H; Gennaro ML; Carter EJ; Martin W; De Groot AS
    Tuberculosis (Edinb); 2005; 85(1-2):95-105. PubMed ID: 15687033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing a preventive immunization approach against insect bite hypersensitivity using recombinant allergens: A pilot study.
    Jonsdottir S; Hamza E; Janda J; Rhyner C; Meinke A; Marti E; Svansson V; Torsteinsdottir S
    Vet Immunol Immunopathol; 2015 Jul; 166(1-2):8-21. PubMed ID: 26004943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.